Introduction {#s1}
============

It is important to determine the conditions in which unprotected sexual intercourse carries a negligible risk of HIV transmission, both for prevention and for establishing guidelines. Several studies have shown that plasma HIV-RNA suppression by combined antiretroviral therapy (cART) is associated with a huge reduction in the risk of sexual HIV transmission in serodifferent couples [@pone.0069686-Attia1]--[@pone.0069686-Cohen1]. In January 2008 the Swiss Federal AIDS Commission stated that HIV-infected people on effective cART without other sexually transmitted diseases may be considered "sexually noninfectious" [@pone.0069686-Vernazza1]. Subsequent French recommendations considered that unprotected sex was a possible alternative to medically assisted reproduction under the same conditions [@pone.0069686-Yeni1]. Nevertheless, small amounts of HIV-RNA and/or HIV-DNA are frequently present in the genital tract of women on cART, even with recent cART regimens that regularly achieve plasma HIV-RNA viral loads (PVL) below 50 cp/mL [@pone.0069686-Neely1]--[@pone.0069686-Launay1]. In cervicovaginal secretions (CVS), cell-free HIV-RNA viral load is the best predictor of the risk of sexual transmission, and cell-associated HIV-DNA is also a marker of potential infectiousness [@pone.0069686-Spinillo1], [@pone.0069686-Baeten1]. The presence of HIV-DNA corresponds to the detection of infected cells (i.e. leukocytes) in the genital tract. The level of HIV-DNA may reflect the overall level of HIV infection in the body and/or be a consequence of the persistence of local residual inflammation, which may be maintained or triggered by a bacterial, viral or fungal infection. In addition, the slightest distribution of some antiretroviral drugs in the genital tract, which might contribute to maintain productive infected cells, can lead to a viral compartmentalization. In principle, therefore, the presence of at least one of these markers would imply the need for sexual abstinence and/or systematic condom use, ruling out "normal" sexuality and reproduction. To our knowledge, the residual risk of HIV transmission to male partners of women on long-term effective cART has not been studied in terms of both HIV-RNA and HIV-DNA levels in the genital tract.

The aims of this study were to determine the amounts of HIV-RNA and HIV-DNA in the genital tract of women on long-term effective cART, to identify factors predictive of residual viral shedding in the genital tract, and to assess the risk of sexual transmission to their male partners.

Patients and Methods {#s2}
====================

Population and study design {#s2a}
---------------------------

This was a cross-sectional study. We recruited consecutively non-pregnant HIV-1-infected female outpatients aged 18 years or more who were attending the Department of Infectious Diseases of Orleans Regional Hospital (France) for scheduled routine cervical dysplasia/cancer screening. Women on cART who had had PVL levels below 50 copies/mL for at least 6 months and who had no genital symptoms were invited to join the study. Patients experiencing more than one blip (PVL 50--200 cp/mL framed by PVL \<50 cp/mL) per year were excluded. Patients were asked about their adherence to treatment during the past 3 months, and were asked to avoid sexual intercourse, douching and the use of intravaginal procedures or inserts during 48 hours before the study visit.

A "viremic" group of HIV-1-infected women with PVL \>100 copies/mL, with or without cART, was also recruited in order to validate the biological methods.

All the participants gave their written informed consent, and the study protocol was approved by our institutional ethics committee (Comité d\'éthique Recherche du Centre Hospitalier Régional d\'Orléans). Counselling to avoid unprotected sex was systematically provided to study participants.

Sample collection {#s2b}
-----------------

Blood and genital samples were collected on the same day, between the 10th and 20th days of the menstrual cycle to avoid contamination by menses. The same practician collected all genital samples throughout the study.

Blood analyses included T cell counts, PVL, HIV-DNA quantification in peripheral blood mononuclear cells (PBMCs), and syphilis serology. Urine was systematically tested for *Chlamydia trachomatis* by PCR (Real Time CT, Abbott).

Genital specimens were collected after careful visual examination, using a speculum. First, vaginal swabbing was performed to screen for fungal and bacterial infections, by wet mount, Gram staining, white and red blood cell counts, and culture in appropriate media (including medium specific for *Neisseria spp*). Yeast cells were detected by light microscopy on a saline wet preparation and were identified by direct examination. Bacterial vaginosis was diagnosed with the Nugent score [@pone.0069686-Nugent1]. CVS were then collected for viral assays. Specimens were obtained by vaginal lavage (douching) with 6 mL of phosphate-buffered saline inserted into the vagina, left to pool for 1 min, then reaspirated and re-inserted 3 to 5 times, as described by Belec *et al* [@pone.0069686-Blec1]. Cervicovaginal lavage fluid (CVL) was immediately stored at −80°C for pooled analysis. An additional swab was collected for Y chromosome detection in CVL of women with detectable vaginal VL, in order to rule out contamination by an HIV-positive male partner. Finally, cervical cytology was performed.

Virological methods {#s2c}
-------------------

### Quantification of HIV-1 RNA in blood and CVS {#s2c1}

Plasma and vaginal HIV-RNA viral loads were determined by RT-PCR, using the Abbott RealTime HIV-1 assay, as recommended by the manufacturer (Abbott Molecular Inc., Des Plaines, IL, USA, 2007), in 1 ml of each sample. The positivity cut off was 40 copies/mL for both blood and genital samples. The study group was subdivided around the sensitivity cut off of the Abbott RealTime assay, into a group with undetectable PVL (\<20 cp/mL) and a group with residual viremia (RV) (20\<PVL\<40 cp/mL). Because most current guidelines and recent reports consider \<50 cp/mL as the standard threshold for "undetectability", we integrated PVL values between 40 and \<50 cp/mL in the RV group.

### Quantification of cell-associated HIV-DNA in blood and CVS {#s2c2}

HIV-DNA was extracted from 200 µL of blood and 1 mL of CVL, using the Nucleospin blood kit (Macherey-Nagel). Total cell-associated HIV-DNA was quantified in these extracts by using the ANRS ultrasensitive real-time PCR method (Biocentric, Bandol, France), as previously described (amplification of the LTR region), in quadruplicate [@pone.0069686-AvettandFnol1]. [Results](#s3){ref-type="sec"} were expressed as log~10~ copies per million PBMCs and as log~10~ copies per million vaginal cells.

### Detection of herpes simplex virus type 2 (HSV-2) DNA in CVS {#s2c3}

HSV-2 DNA was detected using a qualitative, real-time PCR assay (HSV2 R-geneTM, Argene Inc., NY, USA) (detection threshold: 50 copies/mL).

Estimation of sexual exposure among male partners {#s2d}
-------------------------------------------------

Women in the study group were interviewed using a structured questionnaire that included condom use with stable male partners. When a woman said she had unprotected intercourse, the latest HIV serologic status of her partner(s) was collected. The partners were re-tested if their last test was done more than 3 months before the study day. The stated monthly frequency of sexual intercourse and the total duration of sexual exposure of unprotected male partners were used to estimate the total number of unprotected sexual acts during the years preceeding the study, by multiplying the monthly frequency of intercourse by the time until the last negative HIV test. Only the period during which the women were on cART was considered in these analyses (i.e.: we excluded from analysis all cases where the male partner was known to be seropositive for HIV before cART was started in his partner).

Statistical analyses {#s2e}
--------------------

Categorical data were compared with Fisher\'s exact test or the χ^2^ test, and continuous variables with the Kruskall-Wallis or Mann-Whitney U test. The association between outcomes of interest and various factors, including all demographic and immuno-virological data at baseline, were tested in a multivariate logistic regression model. Linear correlations were analyzed with Pearson\'s test. MedCalc statistical software (MedCalc Software, Mariakerke, Belgium) was used for all analyses.

Results {#s3}
=======

Population characteristics {#s3a}
--------------------------

Ninety-seven women were enrolled, 81 in the study group (PVL \<50 cp/mL) and 16 in the viremic group (PVL \>100 cp/mL). Overall, two patients only declined to join the study. In the study group, the median duration of PVL \<50 cp/mL was 44 months \[IQR: 21--68\]: among them 58 patients (72%) had PVL \<20 cp/mL and 23 (28%) had residual viremia (20\<PVL\<50 cp/mL) at the time of inclusion. The viremic group comprised 9 cART-naïve patients and 7 patients with detectable PVL on cART. The clinical and virological characteristics of the patients are summarized in [Table 1](#pone-0069686-t001){ref-type="table"}.

10.1371/journal.pone.0064028.t001

###### Baseline characteristics of women included in the study group (n = 81) and viremic group (n = 16).

![](pone.0069686.t001){#pone-0069686-t001-1}

                                                                         Study group                         Viremic group
  -------------------------------------- --------------------- -------------------------------- ----------------------------------------
  Age, years                                                                  40                                  35,5
                                                                        \[35\]-\[50\]               [@pone.0069686-Freeman1]-\[50\]
  Ethnicity, n (%)                                                                              
                                          Sub-Saharan African              58 (72)                              12 (75)
                                               European                       19                                   4
                                                 Other                        4                                    0
  Heterosexual HIV transmission, n (%)          74 (91)                    16 (100)             
  CDC staging, n                                                                                
                                                   A                          49                                   12
                                                   B                          16                                   2
                                                   C                          16                                   2
  Co-infection, n                                                                               
                                                 none                         68                                   14
                                                  HBV                         6                                    2
                                                  HCV                         7                                    0
  Lowest CD4+ T cell count, /µL                   230                        303                
                                                                         \[147-305\]                          \[116-423\]
  Highest plasma HIV-RNA, log/mL                  5.1                        4.8                
                                                                         \[4.6-5.6\]                          \[3.9-5.7\]
  Plasma HIV-RNA, log/mL                         \<1.7                       3.7                
                                                                                                              \[3.3-4.8\]
  Vaginal HIV-RNA, log/mL                        \<1.6                       2.2                
                                                                                                             \[\<1.6-2.4\]
  HIV-DNA in blood, log/10^6^ PBMCs               2.7                        2.8                
                                                                         \[2.4-3.1\]                          \[2.4-3.1\]
  HIV-DNA in vagina, cp/10^6^ cells                0                          0                 
                                                                           \[0-6\]                              \[0-11\]
  CD4+ T cell count, /µL                          663                        499                
                                                                         \[467-889\]                          \[316-627\]
  \% CD4+ T cells                                                             33                                   24
                                                                [@pone.0069686-Delany1]-\[40\]   [@pone.0069686-AvettandFenoel1]-\[36\]
  CD4+/CD8+ ratio                                                            0.9                                  0.5
                                                                         \[0.6-1.3\]                          \[0.3-0.9\]
  Vaginal colonization, n (%)                   24 (30)                    11 (69)              
  median \[IQR\]                                                                                

Blood and genital HIV-RNA levels {#s3b}
--------------------------------

In the study group, all 81 women with sustained PVL \<50 cp/mL had CVL HIV RNA levels below 40 copies/mL. In the viremic group, the median VL was 3.7 log~10~ cp/mL \[3.3--4.8\] in plasma and 2.2 log~10~ cp/10^6^ cells \[\<1.6--2.4\] in CVL. We found a strong positive correlation between HIV-RNA levels in plasma and CVL (r = 0.566; p = 0.028) ([Fig. 1](#pone-0069686-g001){ref-type="fig"}). The median HIV-RNA level was at least 10 times higher in plasma than in CVL.

![Correlation between HIV-RNA viral loads in paired plasma and cervicovaginal samples in the viremic group.\
Circles represent women with plasma HIV-RNA viral load \>100 cp/mL (viremic group). The solid line is the regression line for this population.](pone.0069686.g001){#pone-0069686-g001}

Blood and genital HIV-DNA levels {#s3c}
--------------------------------

HIV-DNA levels in PBMCs and vaginal cells were similar in the study and viremic groups ([Table 1](#pone-0069686-t001){ref-type="table"}). There was a weak positive correlation between PBMCs and vaginal cells-associated HIV-DNA levels in the overall population (r = 0.26; p = 0.01) ([Fig. 2](#pone-0069686-g002){ref-type="fig"}), and also in the study group (r = 0.20; p = 0.08) and the viremic group (r = 0.57; p = 0.03).

![Correlation between HIV-DNA levels in paired blood and genital samples in the whole population (study and viremic groups).\
Solid squares represent women with plasma HIV-RNA viral load \<50 cp/mL (study group), and circles women with plasma HIV-RNA viral load \>100 cp/mL (viremic group). The solid line is the regression line for the whole population.](pone.0069686.g002){#pone-0069686-g002}

HIV-DNA was detected in vaginal cells of 29/78 patients (37%) in the study group and 7/15 patients (47%) in the viremic group (p = 0.6). In the study group, HIV-DNA was detected in vaginal cells of 12/33 patients with RV and 17/55 of those with PVL\<20 cp/mL (p = 0.12). In patients with RV the median HIV-DNA level in vaginal cells was 2 cp/10^6^ cells \[IQR = 0--10\] versus 0 cp/10^6^ cells \[IQR = 0--3\] in those with PVL\<20 cp/mL (p = 0.097).

Microbiology findings in the genital tract {#s3d}
------------------------------------------

In the study group, although the patients all denied genital symptoms, 29/81 (36%) had at least one laboratory-diagnosed vaginal colonization: 17 (21%) had bacterial vaginosis and 8 (9%) had vaginal candidiasis (1 had dual colonization) ([Table 1](#pone-0069686-t001){ref-type="table"} and [2](#pone-0069686-t002){ref-type="table"}). No cases of *Trichomonas*, *N. gonorrhoeae* or *C. trachomatis* vaginal infection were found. None of the women self-declared genital ulcers and none had evidence of ulceration on visual inspection. Only one patient had asymptomatic HSV-2 shedding.

10.1371/journal.pone.0064028.t002

###### Analysis of characteristics associated with HIV-DNA detection in the genital tract of women included in the study group.

![](pone.0069686.t002){#pone-0069686-t002-2}

                                                                                    Undetectable                                        Detectable                              
  ----------------------------------------- --------------------- ------------------------------------------------ ---------------------------------------------------- ------- -------
  Age, years                                                                             40                                                38,0                          0.18   
                                                                                   \[35\]-\[52\]                                      \[34\]-\[44\]                             
  Ethnicity, n                                                                                                                                                           0.08   
                                             Sub-Saharan African                         34                                                 21                                  
                                                  European                               14                                                 5                                   
                                                    Other                                1                                                  3                                   
  Heterosexual HIV transmission, n (%)             45 (92)                            26 (90)                                              0.6                                  
  CDC staging, n                                                                                                                                                         0.009  
                                                      A                                  37                                                 12                                  
                                                      B                                  7                                                  8                                   
                                                      C                                  5                                                  9                                    0.006
  Co-infection, n                                                                                                                                                         0.3   
                                                    none                                 42                                                 23                                  
                                                     HBV                                 2                                                  4                                   
                                                     HCV                                 5                                                  2                                   
  Lowest CD4+ T cells, /µL                                                               18                                                 12                           0.005  
                                                                   [@pone.0069686-Nugent1]-[@pone.0069686-Fiore1]   [@pone.0069686-Henning1]-[@pone.0069686-Debiaggi1]          
  Highest plasma HIV-RNA, log/mL                     4.9                                5.4                                                0.06                                 
                                                                                    \[4.6-5.4\]                                        \[4.8-5.7\]                              
  Time from HIV diagnosis to treatment, y            0.4                                0.5                                                0.9                                  
                                                                                     \[0.1-3\]                                         \[0.1-3.1\]                              
  CD4+ T cell count, /µL                                                                709                                                613                           0.15   
                                                                                    \[496-894\]                                        \[408-800\]                              
  \% CD4+ T cells                                                                        36                                                 30                           0.009  
                                                                           [@pone.0069686-Wawer1]-\[41\]                     [@pone.0069686-Shekelle1]-\[37\]                   
  CD4+/CD8+ ratio                                                                        1                                                 0.7                           0.02   
                                                                                    \[0.7-1.4\]                                        \[0.6-1.1\]                              
  Residual viremia, n (%)                                                             11 (22)                                            12 (41)                         0.13    0.04
  HIV-DNA in blood, log/10^6^ PBMCs                  2.7                                2.8                                                0.13                                 
                                                                                     \[2.3-3\]                                         \[2.5-3.1\]                              
  Time with plasma HIV-RNA \<50 cp/mL, mo            48                                  36                                                0.17                                 
                                                                                     \[23-72\]                                          \[16-65\]                               
  cART regimens, n                                                                                                                                                        0.5   
                                                   3 NRTIs                               3                                                  1                                   
                                              2 NRTIs + 1 NNRTI                          20                                                 11                                  
                                               2 NRTIs + 1 PI                            24                                                 14                                  
                                               2 NRTIs + 1 II                            1                                                  3                                   
  Vaginal colonization, n (%)                                                         12 (24)                                            10 (34)                          0.5   
  White blood cells/field, n                         40                                  10                                                0.08                                 
                                                                                     \[0-400\]                                           \[0-50\]                               
  Vaginal cells/field, n                                                                100                                                 70                            0.3   
                                                                                     \[43-188\]                                         \[43-100\]                              
  median \[IQR\]                                                                                                                                                                

Abbreviations : **HBV: hepatitis B virus; HCV: hepatitis C virus; II: integrase inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI: non nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.**

Factors associated with the presence of HIV-DNA in vaginal cells of patients in the study group {#s3e}
-----------------------------------------------------------------------------------------------

In univariate analysis, the presence of HIV-DNA in CVL was associated with the CDC stage, the CD4+ nadir, the current %CD4+, and the current CD4+/CD8+ ratio ([Table 2](#pone-0069686-t002){ref-type="table"}). There was no correlation between the CVL HIV-DNA level and the duration of undetectable PVL, vaginal colonization, or the class of cART regimen.

In multivariate analysis, only a history of AIDS-defining illness (OR = 11; 95%CI = 2--61) and current residual viremia (OR = 3.4; 95%CI = 1.1--10.9) were associated with an increased risk of HIV-DNA detection in vaginal cells.

Estimated risk of HIV transmission to male partners {#s3f}
---------------------------------------------------

All 81 women in the study group said they had only one, stable partner, and 23 of them (28.4%) said they routinely had unprotected intercourse. These women said they had sex 13 times a month on average, over a mean study period of 46 months \[range: 8--132 months\], yielding an estimated 14 000 exposures among their partners. Genital HIV-DNA was detected in 8 (34.8%) of the women who had unprotected sexual intercourse (median: 10 cp/10^6^ cells \[range: 6--442\]). All of these women had CD4+ cell counts above 500/mm^3^ and half of them had residual plasma viral load. Overall, none of the male partners was found to be HIV positive at the last test they underwent.

Discussion {#s4}
==========

This is one of the largest investigation of genital HIV-1 shedding (including both HIV-RNA and HIV-DNA) among women on long-term effective cART in an industrialized country. Another strength of this study is that the male partners\' HIV serostatus was also determined. We found that HIV-RNA was undetectable in the genital tract of women who had sustained plasma viral load below 50 copies/mL on cART, regardless of the drugs used, and that none of their male partners became infected during the study period. However, a low level of HIV-DNA was frequently detected in these women\'s cervicovaginal secretions, raising the possibility of residual infectiousness. Noteworthy, we found that the detection of HIV-DNA in the genital tract was statistically linked to the presence of a residual viremia.

We found that 39.5% of women with undetectable PVL had detectable HIV-DNA in the genital tract, a rate very similar to those previously reported (median 34%, IQR = 30--40) [@pone.0069686-Henning1]--[@pone.0069686-Spinillo1], [@pone.0069686-Shaheen1]--[@pone.0069686-Graham1]. Overall, there was a positive correlation between HIV-DNA shedding in the genital tract and the level of HIV-DNA in PBMCs, although this correlation was less pronounced than the one we previously found between gut-associated lymphoïd tissue and blood [@pone.0069686-AvettandFenoel1]. Noteworthy, one of the two factors independently associated with HIV-DNA shedding in the genital tract was a residual viremia. A low level of plasma HIV-RNA could be a marker of ongoing replication in HIV sanctuaries, particularly the genital tract where some antiretroviral drugs diffuse poorly [@pone.0069686-Kwara1], [@pone.0069686-Taylor1]. The infectiousness of HIV-DNA-containing vaginal cells is unclear. Baeten *et al* reported cases of HIV transmission among male partners of untreated women with undetectable HIV-RNA in CVS [@pone.0069686-Baeten1]. HIV-DNA in CVS could also be a surrogate marker for residual genital HIV-RNA transcription below the detection limit of current methods.

Although there is a good correlation between HIV-RNA viral load in paired blood and genital samples, it was recently reported that genital HIV-RNA shedding is predictive of heterosexual HIV transmission, independently of the plasma HIV-RNA concentration [@pone.0069686-Baeten1]. Prospective studies have shown that effective cART rapidly reduces both HIV-RNA and HIV-DNA shedding in CVS, but whether or not this persists over several years has rarely been investigated [@pone.0069686-Henning1]--[@pone.0069686-Spinillo1], [@pone.0069686-Debiaggi1], [@pone.0069686-Graham1]. All the patients studied here were taking one of the optimized cART regimens currently used in Europe, based on systematic genotyping; in addition, self-reported adherence was excellent (data not shown) and follow-up took place in optimal conditions, contrary to previous studies in resource-poor settings [@pone.0069686-Ivers1]. Likewise, few protease inhibitor (PI)-based regimens are used in most sub-Saharan countries, while PI appear to be more effective than NNRTI in suppressing genital HIV-RNA shedding [@pone.0069686-Neely1], [@pone.0069686-Graham1], [@pone.0069686-Quinn1]--[@pone.0069686-Nagot1]. Finally, pretreatment HIV genotyping is not routinely used in poor countries. This could lead to lower efficacy in case of primary resistance, particularly in countries where nevirapine monotherapy is generally used to prevent mother-to-child transmission [@pone.0069686-Shekelle1]. Of note, we found no association between the class of cART (in particular PI vs. NNRTI) and genital viral shedding.

One important limitation of this study is its cross-sectional nature. The results obtained here do not rule out the possibility that HIV-RNA is occasionally shed in the genital tract of HIV-infected women with undetectable PVL, as reported elsewhere [@pone.0069686-CuUvin1], [@pone.0069686-Launay1]. It is noteworthy that we found lower rates of viral shedding in CVS than previously reported [@pone.0069686-Neely1]--[@pone.0069686-Spinillo1], [@pone.0069686-Shaheen1]--[@pone.0069686-Graham1], [@pone.0069686-Graham2], [@pone.0069686-Fiore1]. However, most previous studies included patients who had intermittent viremia and/or a shorter duration of undetectable PVL. One another limitation is the sampling method we used. Indeed, we performed cervicovaginal lavage prior to any potentially traumatic procedure, as the presence of blood could interfere with shedding measurements. CVL also increases the sampling area and collects a large volume of fluid that can be fractionated for analysis. However, this method leads to dilution of viral particles. In a previous study including untreated viremic women, HIV-1 RNA was detected in respectively 57%, 61% and 79% of vaginal tampons, CVL, and cervicovaginal lavage fluid samples enriched with a cervical swab (eCVL) [@pone.0069686-Delany1]. In an adjusted analysis excluding samples containing microscopic traces of blood, CVL was still 1.4 times (95% CI 1.05 to 1.88; P = 0.022) less sensitive than eCVL [@pone.0069686-Delany1]. Although less sensitive than enriched lavage, the CVL method more closely mimics natural conditions of HIV-1 transmission and avoids blood contamination [@pone.0069686-Delany1]. The long period of PVL suppression and the potent cART regimens used here could also have contributed to the low frequency of HIV-RNA detection. Interestingly, the frequency of HIV-RNA detection in the genital tract of women on cART has tended to fall during the last decade: in 6 studies conducted up to 2007, a median 27% (IQR = 25--30) of women had positive results, while this rate was only 14% (IQR = 11--15) in 4 studies conducted between 2010 and 2011 [@pone.0069686-Neely1]--[@pone.0069686-Spinillo1], [@pone.0069686-Shaheen1]--[@pone.0069686-Graham1], [@pone.0069686-Graham2], [@pone.0069686-Fiore1].

Additional factors such as incomplete adherence to therapy and active sexually transmitted infections may increase the risk of sexual transmission [@pone.0069686-Graham2], [@pone.0069686-Gray1]--[@pone.0069686-Freeman1]. Some intravaginal practices among African women disrupt the vaginal flora, increase the risk of vaginosis, and are associated with intermittent HIV-RNA shedding in the genital tract [@pone.0069686-Low1]. Thus, local inflammation due to intravaginal use of aggressive products, rather than the subsequent vaginosis, could trigger intermittent local HIV-RNA transcription by activated HIV-infected lymphocytes. However, we did not find that genital colonization (bacterial vaginosis or candidiasis) or higher vaginal cell counts were associated with HIV-DNA shedding in the genital tract.

Heterosexual HIV transmission involves interactions between biological and behavioural factors. Thus, it is important to study sexual practices in serodifferent couples. We were surprised that a substantial proportion of the HIV-infected women studied here regularly had unprotected sexual intercourse with their partners, with a cumulative total of 14 000 unprotected exposures. None of the partners was contaminated, in keeping with previous studies in which no HIV infection was noted among serodifferent couples when the index case was on effective cART [@pone.0069686-Attia1], [@pone.0069686-DelRomero1]. Given the limited number of couples, and the observational nature of our study, these results should be considered cautiously. Effective cART has been shown by others to have a strong protective effect on HIV transmission within serodifferent couples [@pone.0069686-Cohen1], but larger studies are still needed to confirm this low risk.

In conclusion, we found that women with long-term suppression of plasma viral load on cART had undetectable HIV-RNA in their cervicovaginal secretions, and that none of their male partners became infected, despite frequently unprotected intercourse. Nevertheless, small amounts of HIV-DNA were detected in half the women, suggesting there may be a low residual risk of sexual transmission. The infectiousness of cell-associated HIV-DNA has to be investigated further.
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